ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 2978

Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult Idiopathic Inflammatory Myopathies (IIM) in an Australian Cohort

Queenie Luu1, Jessica Day2,3, Alix Hall4, Vidya Limaye2,5 and Gabor Major6,7, 1Rheumatology, Bone and Joint Institute, John Hunter Hospital, New Lambton Heights, Australia, 2Rheumatology, The Royal Adelaide Hospital, Adelaide, Australia, 3School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, 4Hunter Medical Research Institute, New Lambton Heights, Australia, 5Discipline of Medicine, University of Adelaide, South Australia, Adelaide, Australia, 6Rheumatology, Bone and Joint Institute, John Hunter Hospital, Newcastle, Australia, 7University of Newcastle, Newcastle, Australia, Newcastle, Australia

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: classification criteria, diagnostic criteria and myositis, Validity

Session Information

Date: Wednesday, October 24, 2018

Title: 6W022 ACR Abstract: Muscle Biology, Myositis & Myopathies II: Clinical & Misc Topics (2976–2981)

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: EULAR/ACR recently approved classification criteria for idiopathic inflammatory myopathies (IIM) with 93% sensitivity and 88% specificity. An acknowledged limitation of the study is the absence of controls/comparators in the external validation cohort, prompting the authors to call for further validation studies in different populations.

We sought to 1) evaluate the performance of the criteria in an Australian cohort of adult patients with suspected IIM; 2) determine the level of agreement between the EULAR/ACR criteria and traditional criteria (Bohan and Peter, and Targoff); 3) determine the optimal cut-point for Australian patients; 4) assess the effect of including MRI of the musculature or an extended panel of antibodies, as additional ‘risk factors’; 5) assess the effect of extending “endomysial infiltration of mononuclear cells surrounding but not invading myofibres” to include invasion of myofibres.

Methods: Data were collected retrospectively on all consecutive patients referred for muscle biopsy to two large tertiary teaching hospitals. Area under the receiver operator curve (AUC) was calculated to assess the overall performance of the EULAR/ACR criteria. The Youden method was used to determine the optimal cut point. Patients were scored for ‘risk of IMM’ according to the EULAR/ACR criteria and dichotomized into probable/definite and negative/possible groups. The predictive accuracy of the EULAR/ACR criteria was assessed by evaluating the sensitivity and specificity.

Results: Eighty seven of 204 patients had IIM. Overall, the EULAR/ACR criteria had an outstanding level of discrimination (AUC=0.90). Application of the criteria in this cohort however, showed lower sensitivity (71% vs. 93%) but comparable specificity (89% vs. 88%). The optimal cut point of 5.23 (sensitivity 91%, specificity 75%) for this sample was lower than the EULAR/ACR cut point of 6.7. The EULAR/ACR criteria had a moderate agreement with Bohan and Peter (kappa=0.45, 95%CI=0.28, 0.62, p<0.001) and Targoff (kappa=0.40, 95%CI=0.23, 0.57, p<0.001). Inclusion of MRI of the musculature (AUC=0.86, 95%CI=0.79, 0.93), or non-Jo1 myositis specific antibodies (AUC=0.84, 95%CI=0.77, 0.91) improved the ability of the model to identify IIM compared with the EULAR/ACR criteria alone (AUC=0.80, 95%CI=0.75, 0.86). Furthermore, extending the criteria so that endomysial infiltration of mononuclear cells included invasion of myofibres, resulted in a model with a comparable level of accuracy to the original criteria (both AUCs=0.90). However, the sensitivity was slightly improved (75% vs. 71%) while the specificity remained the same (89% vs. 89%).

Conclusion: The EULAR/ACR criteria had an outstanding discrimination between IIM and non-IIM. Application of the criteria to an Australian cohort has shown comparable specificity but lower sensitivity, and lower optimal cut-point than reported. There is moderate agreement with traditional criteria. Addition of MRI of the musculature, or non-Jo1 myositis specific antibodies, improved the ability of the model to identify IIM. Extending the criteria so that endomysial infiltration of mononuclear cells included invasion of myofibres may improve sensitivity.


Disclosure: Q. Luu, None; J. Day, None; A. Hall, None; V. Limaye, None; G. Major, None.

To cite this abstract in AMA style:

Luu Q, Day J, Hall A, Limaye V, Major G. Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult Idiopathic Inflammatory Myopathies (IIM) in an Australian Cohort [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/performance-of-the-2017-european-league-against-rheumatism-american-college-of-rheumatology-eular-acr-classification-criteria-for-adult-idiopathic-inflammatory-myopathies-iim-in-an-australian-co/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-the-2017-european-league-against-rheumatism-american-college-of-rheumatology-eular-acr-classification-criteria-for-adult-idiopathic-inflammatory-myopathies-iim-in-an-australian-co/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology